IQ-1S

IQ-1S (11H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt) is a small molecule inhibitor of c-Jun N-terminal kinases (JNK), specifically targeting JNK1, JNK2, and JNK3. Developed by Montana State University, it is a selective and potent inhibitor with binding affinities (Kd) of 87 nM for JNK3, 360 nM for JNK2, and 390 nM for JNK1. In addition to its kinase inhibitory activity, IQ-1S also functions as an inhibitor of NF-κB and AP-1 activity. Preclinical studies have demonstrated its anti-inflammatory potential by reducing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-10 in macrophages and T cells. The compound has been investigated in animal models for therapeutic applications in inflammatory conditions, including rheumatoid arthritis, sepsis, and hypertension.

Other names

11H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt